Physician profile
Subhendu Narayan
NPI 1427169002
$2,948.39
in general payments reported to CMS, 2019-2025
24 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $196 · 2021: $214 · 2022: $46.98 · 2023: $295 · 2024: $180 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $741.88 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $680.77 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $360.30 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $289.41 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.26 | 2019-2020 | |
| Lilly USA, LLC | $94.67 | 2025 | Omvoh |
| Pfizer INC. | $86.67 | 2019-2020 | |
| Qol Medical, LLC | $73.22 | 2023-2025 | Sucraid |
| Concordia Pharmaceuticals INC. | $62.95 | 2019 | |
| Shionogi INC | $58.34 | 2019 | |
| Intercept Pharmaceuticals, INC. | $45.76 | 2023-2024 | Ocaliva |
| Mauna Kea Technologies, INC. | $44.78 | 2019 | |
| Merck Sharp & Dohme LLC | $34.56 | 2019 | |
| Exact Sciences Corporation | $32.41 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $29.63 | 2025 | Zenpep |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $28.66 | 2024 | Iqirvo |
| Ferring Pharmaceuticals INC. | $26.35 | 2019 | |
| Daiichi Sankyo INC. | $24.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $22.21 | 2023 | Andexxa |
| Dova Pharmaceuticals | $21.21 | 2019 | |
| Gilead Sciences, INC. | $20.08 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.77 | 2019 | |
| Allergan, INC. | $16.27 | 2019 | |
| Napo Pharmaceuticals INC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhendu Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.